Drugs / CLLS52
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT03190278 Background | Jun 2017 → Dec 2024 overdue | acute myeloid leukemia | Cellectis S.A. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05607420 Background | Nov 2022 → Aug 2027 expected | B-cell non-Hodgkin lymphoma | Cellectis S.A. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04150497 Background | Oct 2019 → Jun 2026 overdue | B-cell acute lymphoblastic leukemia | Cellectis S.A. | Recruiting | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-08-01 | Cellectis S.A. | FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment cellectis.com ↗ |
| 2023-04-24 | Cellectis S.A. | Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi’s Alemtuzumab cellectis.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CLLS52 | “Biological/vaccine: CLLS52 A monoclonal antibody that recognizes the CD52 antigen Other Names: Alemtuzumab” NCT03190278 ↗ |
| Modality | Monoclonal antibody | “CLLS52 A monoclonal antibody that recognizes the CD52 antigen” NCT03190278 ↗ |
| Target | CD52 | “recognizes a CD52 antigen” NCT04150497 ↗ |